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Pneumocystis Pneumonia in 
AIDS Patients
Pneumocystis is a major cause of pneumonia in im-
munocompromised individuals, including those
with AIDS and those receiving immunosuppres-
sive therapy. During the early stage of the AIDS
epidemic, there were approximately 20,000 cases
of Pneumocystis pneumonia (PcP) per year. The
incidence of PcP started to decline when prophy-
laxis was recommended in 1989 for HIV-infected
patients with a CD4+ cell count less than 200/μL.1,2
A further decline in the incidence of PcP occurred
around 1996 when highly active anti-retroviral
therapy (HAART) became widely used. At present,
PcP occurs mainly as an AIDS-associated illness
in patients who do not know that they are HIV-
positive or who are not compliant with HAART
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Pneumocystis pneumonia (PcP) in humans is caused by Pneumocystis jirovecii, which has recently been 
reclassified as a fungus because its cell wall composition and nucleotide sequences are more similar to
those of fungi. PcP occurs only in immunocompromised individuals such as those with AIDS. Despite the use
of highly active antiretroviral therapy, PcP remains the leading opportunistic infection in AIDS patients.
Based on nucleotide sequence variations in the internal transcribed spacer region of rRNA genes, more than
60 different types of P. jirovecii have been identified. Although type differences do not appear to correlate
with the clinical characteristics of PcP, nucleotide sequence variations of the organism have been useful in
epidemiologic studies. As a result, some recurrent infections are found to be due to re-infection with new
types, and outbreaks due to the same types of P. jirovecii have been identified. Initial diagnosis of PcP is
usually based on symptoms and chest radiography. A characteristic histopathologic feature is the presence
of acellular eosinophilic exudates and organisms in the alveoli. Ultimate diagnosis of PcP is achieved by
demonstration of the organism in induced sputum or bronchoalveolar lavage fluid by tinctorial staining
or polymerase chain reaction (PCR). Among the many different PCR methods, the nested PCR that targets
the large subunit mitochondrial rRNA gene is the most sensitive and specific. Combination of trimethoprim
and sulfamethoxazole is the first choice of drugs for both treatment and prophylaxis of PcP. Other drugs
that can be used include a combination of primaquine and clindamycin, pentamidine, atovaquone, and 
a combination of dapsone and trimethoprim. Pneumocystis organisms have the ability to inactivate the
phagocytic activity of alveolar macrophages and to induce them to undergo apoptosis. This apoptosis is
due to activation of caspase 9 by polyamines that are present in high levels in the lung and alveolar
macrophages during PcP. [J Formos Med Assoc 2008;107(11):830–842]
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therapy. However, PcP is still the most common
opportunistic infection in AIDS patients.3
The Organism
Pneumocystis was first identified as a form of try-
panosome in guinea pigs by Chagas4 and in rats
by Antonio Carinii.5 In 1912, Delanoe and Dela-
noe6 found that it was not a trypanosome and
named it Pneumocystis carinii in honor of Carinii.
Morphologically, P. carinii has the characteristics
typical of protozoa and therefore was considered
as a protozoan. P. carinii is now classified as a
fungus because the composition and structure of
its cell wall7,8 and nucleotide sequences are more
similar to those of fungi than to those of protozoa.
The first molecular biological evidence suggesting
that P. carinii is a fungus was described by Edman
et al.9 They determined the nucleotide sequence
of the 16S rRNA gene of P. carinii and found that
this sequence was more similar to that of fungi
than to that of protozoa. Similar results were
later reported by Stringer et al.10 Additional mo-
lecular information with the same implication
includes the finding that thymidylate synthase
(TS) and dihydrofolate reductase (DHFR) of 
P. carinii are two distinct enzymes,11,12 whereas
those activities in protozoa are contained within
a single bifunctional protein.13 Results of studies
on the P. carinii β-tubulin gene,14,15 5S rRNA
gene,16 mitochondrial rRNA gene and other mito-
chondrial protein genes17 indicate a closer re-
lationship to filamentous fungi than to yeasts.
Pneumocystis is now classified as a member of the
phylum Ascomycota. Although much evidence
suggests that Pneumocystis is a fungus, it is not
susceptible to antifungal drugs such as ampho-
tericin B because of the lack of ergosterol, which
is the major sterol and a hallmark of most fungi.
Taxonomy
Pneumocystis infects many different species of mam-
mals, including human, monkey, horse, pig, rabbit,
ferret, rat, mouse, etc. However, Pneumocystis is
host specific.18 Pneumocystis organisms from rats
do not infect mice, and those from humans do
not infect other animal species, and vice versa.
Although Pneumocystis organisms from different
host species are morphologically similar, analyses
of nucleotide sequences of ribosomal RNA genes
and other loci of Pneumocystis from different hosts
indicate that they are distinct. To reflect this dif-
ference, a trinomial naming system was proposed
in 1994.19 In this system, human P. carinii was
named Pneumocystis carinii f. sp. hominis, and rat
P. carinii was called Pneumocystis carinii f. sp. carinii.
Mouse P. carinii was referred to as Pneumocystis
carinii f. sp. muris, and ferret P. carinii was named
Pneumocystis carinii f. sp. mustelae. This naming
system has proven to be very cumbersome to use;
therefore, another naming system was proposed.20
This new system first adopts the name Pneumocystis
jirovecii, which was first proposed by Frenkel,21 as
the official name for human Pneumocystis. P. carinii
now refers to the original rat Pneumocystis. Mouse
Pneumocystis is now called P. murina, and ferret
Pneumocystis is named P. mustelae.
Strain Variation
Both rat and human Pneumocystis have been found
to have more than one type. Typing of Pneumocystis
organisms is based on the number and size of
chromosomes separated by pulsed-field gel elec-
trophoresis (PFGE) or on nucleotide sequence
variations of certain genetic loci. PFGE studies
reveal that Pneumocystis from various host species
has approximately 15 chromosomes ranging
from 300 kb to 900 kb in size.22,23 Conventional
microbial typing methods such as biochemical
reactions or antigen profiles are not possible be-
cause these methods require large number of 
organisms and Pneumocystis organisms are very
difficult, if not impossible, to culture. Rat Pneumo-
cystis can be cultured for very limited generations
on feeder cells.24–27 An axenic culture system has
been reported,28 but has not been widely used.
Several types of rat Pneumocystis have been detected
by molecular karyotyping based on chromosome
number and length polymorphism.29,30 One of
these types is named P. wakefieldiae (formerly
P. ratti) in memory of Dr A. E. Wakefield. P. wake-
fieldiae differs from P. carinii in genomic se-
quence by 4–7%. P. carinii has 12 electrophoretic
karyotypes, whereas P. wakefieldiae has only one
karyotype.31
More than 60 different types of P. jirovecii have
been discovered.32 These types differ in the nu-
cleotide sequences of the internal transcribed
spacer (ITS) regions (ITS1 and ITS2) of nuclear
rRNA genes.33 Some of these types also have nu-
cleotide sequence variations in the large subunit
mitochondrial rRNA gene.34–36 Although results
of early studies suggested that the development
of PcP was due to activation of latent infection,37
several outbreaks have been described.38–41 An
increase in the incidence of PcP in non-AIDS pa-
tients who were in contact with AIDS patients was
reported.42 There are also reports of transmission
of Pneumocystis from AIDS patients to transplant
recipients.43 The development of typing systems
based on nucleotide sequence variations in the ITS
regions and the large subunit of the mitochondrial
rRNA gene has made it possible to conduct epi-
demiologic studies, and some recurrent infections
were found to be due to re-infection with a new
type.44–46
Approximately 30% of PcP cases are coinfected
with multiple types of Pneumocystis.42,43,47 The
finding that type variation is associated with place
of diagnosis but not with place of birth48,49 suggests
that Pneumocystis infection is acquired. Experimen-
tally, normal mice can be infected when they are
cohoused with Pneumocystis-infected mice. A report
that 12 of 16 renal transplant recipients in the
same hospital developed PcP and were infected
by the same type (Ne) of P. jirovecii also supports
this possibility.41,50 Rabodonirina et al50 found
that five renal transplant recipients and one HIV-
infected patient harbored the same type of P.
jirovecii as the PcP patients they had been in con-
tact with. Using multilocus sequencing typing,
Schmoldt et al40 found a very similar situation in
14 patients who received renal transplants at the
same hospital and were infected with the same
type of P. jirovecii. These observations suggest a
patient-to-patient transmission route. Colonization
of Pneumocystis in individuals with no signs of PcP
has been recognized. There is speculation that
children are reservoirs of Pneumocystis as 85% 
of children have antibodies against Pneumocystis
by 20 months of age.51 Based on PCR results on
nasopharyngeal aspirates, 10% of healthy children
and 15% of those with respiratory symptoms are
considered to have colonization by Pneumocystis.
In adults, 10–69% of nasopharyngeal aspirates
from HIV-infected patients are positive for Pneumo-
cystis PCR.52–54 Most healthy people are Pneumocys-
tis free,55 but Pneumocystis can be detected in
7–19% of patients with respiratory illness.56–58
Diagnosis of Pneumocystis Pneumonia
Patients with PcP usually develop fever, shortness
of breath, substernal tightness, and nonproductive
cough. Their chest radiographs exhibit patchy con-
solidation with bilateral interstitial infiltrates. His-
topathologically, the alveoli of PcP patients are
filled with acellular eosinophilic exudates and
Pneumocystis organisms. Laboratory diagnosis of
PcP is usually achieved by demonstrating the
presence of Pneumocystis organisms in induced
sputum or bronchoalveolar lavage (BAL) fluid.
The success rate of using induced sputum for di-
agnosis of PcP ranges from 50–90%.59 Since it is
noninvasive, it is usually done first. BAL follows if
induced sputum fails to yield satisfactory results.
Pneumocystis has two different morphological
forms, trophozoites and cysts. Diff-Quik, a mod-
ified Wright’s Giemsa stain, is commonly used 
to visualize trophozoites, and Grocott-Gomori me-
thenamine silver (GMS) is used to stain cysts.60–62
Calcofluor white (CW) stain, in which the active
ingredient cellufluor nonspecifically binds to 
β-linked polysaccharides such as β-glucan, chitin
and cellulose, is also commonly used. Immunoflu-
orescence staining, such as MeriFluor (MF) Pneu-
mocystis (Meridian Bioscience Inc., Cincinnati,
OH, USA) using monoclonal antibodies, is also
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commonly done.63–65 A recent study comparing
these four different staining methods on 310 res-
piratory specimens concludes that all of these
methods have a specificity greater than 94% but
their sensitivities range from 48.4% to 90.8%,
with Diff-quick the least sensitive (48.4%), fol-
lowed by CW (73.8%), GMS (76.9%), and MF
(90.8%). Among these, only CW and GMS have
positive and negative predictive values greater
than 90%.66
Many different PCR methods for diagnosis of
PcP have been reported; the targets of these meth-
ods include dihydropteroate synthase (DHPS),
dihydrofolate reductase (DHFR), thymidylate
synthase, β-tubulin, cdc2 gene, the ITS of the
rRNA, 5S rRNA, 18S rRNA, major surface glyco-
protein (MSG), mitochondrial large subunit rRNA
(mtLSUrRNA), and mitochondrial small subunit
rRNA.67–80 A recent study comparing the effi-
ciency of nine different PCR methods for diagnosis
of PcP found that the mtLSUrRNA nested PCR is
the most sensitive and specific method for detec-
tion of P. jirovecii in sputum, tracheal aspirates,
BAL fluids, or lung biopsy tissues.65 The primers for
the first round of this nested PCR are pAZ102-E
(GATGGCTGTTTCCAAGCCCA) and pAZ102-H
(GTGTACGTTGCAAAGTACTC) that amplify a frag-
ment of 346 bp, and those for the second round
are pAZ102-X (GTGAAATACAAATCGGACTAGG)
and pAZ102-Y TCACTTAATATTAATTGGGGAGC.
The final PCR product is 260 bp.
Prophylaxis and Treatment
The first choice of drug for treatment of PcP is
trimethoprim-sulfamethoxazole.81,82 The second
choice is a combination of primaquine and 
clindamycin for those who are allergic to sulfa.
Pentamidine, atovaquone, and a combination of
dapsone and trimethoprim are alternative choices.
For prophylaxis, trimethoprim-sulfamethoxazole
is also the first choice, followed by dapsone,
aerosolized pentamidine, and atovaquone. Sulfa-
methoxazole and dapsone inhibit the folate bio-
synthesis enzyme DHPS, whereas trimethoprim
inhibits DHFR. Sulfamethoxazole is a very widely
used antibiotic, and bacteria resistant to this drug
due to DHPS mutations are very common. Similar
mutations on Pneumocystis DHPS have been 
discovered,83–88 suggesting the occurrence of 
sulfamethoxazole-resistant Pneumocystis isolates.
Evidence indicating that Pneumocystis DHPS mu-
tation is due to exposure to sulfamethoxazole is
the observation that the mutation at amino acid
position 55 or 57 is found in Pneumocystis isolates
in 62–100% of patients receiving prophylaxis and
in only 11–47.5% of those from patients not re-
ceiving prophylaxis.84,85,87–91 Mutations in the
Pneumocystis DHFR gene have also been found
and correlated with failure of prophylaxis.90
Atovaquone is structurally similar to ubiquinone;
it binds to cytochrome b. Mutations on Pneu-
mocystis cytochrome b have also been detected.92–94
Approximately 30% of Pneumocystis isolates from
patients receiving atovaquone have the mutation,
whereas only 6% of those from patients with no
atovaquone exposure have the mutation.93 This
observation suggests that Pneumocystis cytochrome
b mutation is inducible and may render Pneu-
mocystis resistant to atovaquone.
Immune Responses
Both cellular and humoral immune systems are
important in defense against Pneumocystis infection.
The CD4+ T lymphocyte is critical as most patients
with PcP have a very low CD4+ T-cell count.95–98
Furthermore, mice depleted of CD4+ T lympho-
cytes by anti-CD4+ antibodies develop PcP when
they are inoculated with Pneumocystis organisms.
The CD8+ T lymphocyte may be less important
than the CD4+ T lymphocyte because CD8+ T-
lymphocyte-depleted animals can still clear a Pneu-
mocystis infection.99 However, CD8+ T lymphocytes
do play a role in host defense against the infection
as depletion of both CD8+ and CD4+ T lympho-
cytes in animals results in a more severe PcP than
those with depletion of only CD4+ T lymphocytes.
The role of the humoral immune system in
the host response to PcP is suggested by the 
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observations that SCID mice require B lympho-
cytes to clear Pneumocystis organisms,100 and that
agammaglobulinemia patients develop PcP de-
spite the presence of an intact cellular immune
system.98,101,102 In addition, intraperitoneal injec-
tion of sera from mice recovered from PcP confers
protection against PcP to CD4+ lymphocyte-
depleted mice.103 Subcutaneous injection of anti-
bodies against Pneumocystis organisms also confers
partial protection against PcP in rats.32 However,
passive immunity alone is not sufficient because
mouse pups born from PcP dams do not clear the
transtracheally inoculated Pneumocystis organisms
until they are of an age to mount a full immune
response;104 however, these mice have increased
levels of IgG in their lungs and sera and clear the or-
ganisms sooner than those born to naïve dams.105
Active immunization is possible using soluble
Pneumocystis proteins106 or viable organisms107 as
antigens. Although immunization with the major
surface glycoprotein (MSG, also called glycopro-
tein A) from P. murina induces an antibody re-
sponse comparable to that of whole organisms, it
is not protective in T-cell depleted mice.108 Similar
results have been observed in rats; both native
MSG and a recombinant fragment of MSG confer
only partial immunity in immunosuppressed rats,
reducing organism load but not preventing in-
fection.109 An antigen referred to as A12, which is
homologous to P. carinii Kex1, shows promise as
a vaccine candidate. Mice immunized with the
A12-thioredoxin fusion developed a good anti-
body response. When these mice were CD4+ T-cell
depleted and were then challenged with Pneumo-
cystis, 70% were resistant to infection and were
completely free of the organism.110 The role of 
B lymphocytes in defense against Pneumocystis
infection is shown by the observation that B 
lymphocyte-deficient mice are naturally suscep-
tible to Pneumocystis infection.111 B lymphocytes
appear to play a vital role in the generation of
CD4+ memory T cells in response to Pneumocystis
infection as CD4+ T-cells from normal mice mount
immune responses and help the clearance of Pneu-
mocystis organisms in SCID mice, but those from
B cell-deficient mice fail to control the infection.112
The Major Surface Glycoprotein
The trophozoites of Pneumocystis are coated with
MSG, which is encoded by multiple genes.113
MSG is the most abundant protein of Pneumocystis
organisms with a molecular weight of approxi-
mately 120 kD. Similar to the variable surface
glycoprotein of trypanosomes, Pneumocystis MSG
also undergoes antigenic variation; this may be
the reason why MSG fails to confer complete im-
munity against Pneumocystis infection on the host.
It has been estimated that Pneumocystis contains
approximately 100 different MSG genes located
on different chromosomes;114,115 however, only
one MSG gene is expressed at any one time,116–118
and only the MSG gene located at the MSG ex-
pression site is expressed. The MSG expression site
is located close to the telomere of a chromosome
and contains an upstream conserved sequence
(UCS). This sequence is present at the 5’ end of
all MSG mRNA,119 but the mature MSG protein
does not contain the UCS peptide.120 Translo-
cation of a MSG gene to the expression site is
thought to occur by homologous recombination
at the conserved recombination junction element
(CRJE), which is located between the expression
site and the MSG gene that is linked to the 
expression site.119 The CRJE sequence contains 
a dibasic sequence that can be cleaved by a kexin-
like (or subtilisin-like) protease121–125 to remove
the UCS sequence. MSG is thought to mediate
attachment of the organism to type I alveolar ep-
ithelial cells and has been shown to bind to host
factors such as surfactant proteins, vitronectin,
and fibronectin126 via a glycophosphatidylinosi-
tol anchor located at the carboxyl terminus.127
MSG is very heavily mannosylated.128–130 Recom-
binant MSG fragments have been used to study
the serologic response against Pneumocystis in-
fection, and sera from greater than 60% of 
HIV-infected patients with PcP reacted with the
carboxyl terminal fragment of MSG, referred to
as MsgC.131 The cell wall of Pneumocystis cysts is
rich in β-1,3-glucan,7,132 and the gene encoding
the catalytic subunit of β-1,3-glucan synthase has
been identified.133
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Effects of Pneumocystis Infection on
Alveolar Macrophages
In animal experiments, transtracheally inoculated
Pneumocystis organisms are not cleared in alveolar
macrophage-depleted rats,134 indicating that alve-
olar macrophages play an important role in the
clearance of Pneumocystis organisms. In addition,
administration of granulocyte/macrophage-colony
stimulating factor (GM-CSF), which activates
alveolar macrophages during Pneumocystis infec-
tion,135 decreases the severity of PcP.136 These 
results demonstrate the importance of the alveolar
macrophage in the response to PcP. Alveolar mac-
rophages interact with Pneumocystis organisms
through various types of receptors, including the
Fc-γ receptor,112 complement receptor,137 scavenger
receptor,138 mannose receptor,139 and dectin-1,
which recognizes β-glucan.140–142 Recently, Toll-
like receptor 2 (TLR2) was shown to also interact
with Pneumocystis organisms.143,144 TLR2 is a pat-
tern recognition receptor for a large variety of 
ligands such as peptidoglycan, lipoprotein, lipopep-
tide, and zymosan.145 Activated TLR2 transduces
signals through a myeloid differentiation factor 88
(MyD88)-dependent pathway, inducing nuclear
translocation of the transcription factor nuclear
factor-kappa B (NF-κB). NF-κB activation is crucial
for the production of proinflammatory cytokines
and chemokines that initiate the host inflamma-
tory response. In TLR2 knockout (TLR2-/-) mice
with PcP, pulmonary inflammation was found to
be much milder than that in normal mice with
PcP.144 However, these mice had much higher 
organism loads and died at least 1 week sooner
than wild type mice with PcP. This observation in-
dicates that inflammation is a normal host defense
against PcP and cannot be completely inactivated.
Inflammation is due to recruitment of immune
cells into infected tissue. These cells may include
lymphocytes, neutrophils, monocytes and macro-
phages. They serve as the effector cells for the
clearance of microorganisms. However, excessive
inflammation may cause tissue damage. In fact,
inflammation is considered to be the major cause
of lung damage in PcP. Wright et al146 found that
immune-mediated inflammation directly impaired
pulmonary function during PcP. A recent study
showed that sensitized CD8+ T cells failed to clear
organisms but accelerated the onset of lung injury
during PcP.147 CD8+ cells mediating lung damage
during PcP have been shown to be dependent on
MHC class I expression on non-bone marrow de-
rived cells such as epithelial and endothelial cells,
and the continued presence of Pneumocystis or-
ganisms.148 However, the mechanisms by which
CD8+ T cells cause lung damage during PcP are
still unclear. Surprisingly, neutrophils have been
shown to play no role in lung damage during PcP,
although an elevated number of neutrophils was
correlated with poor outcome of PcP.147
Alveolar macrophages can produce interleukin
(IL)-8, which attracts neutrophils and lympho-
cytes by chemotaxis as well as IL-1β, tumor
necrosis factor (TNF)-α, IL-6, and GM-CSF, which
participate in granulomatous lung inflamma-
tion.136,139,149–152 Alveolar macrophages process
and present antigens to naive T lymphocytes, 
activating them to become helper or cytotoxic 
T-cells. Alveolar macrophages can be activated by
Pneumocystis MSG or the whole organism to release
inflammatory mediators such as TNF-α and eicos-
anoid metabolites prostaglandin E2 and leuko-
triene B4.153–155 This activation is enhanced by
vitronectin or fibronectin, which accumulates in
the lung during PcP.156 Many investigators have
investigated clearance of Pneumocystis organisms by
alveolar macrophages. When alveolar macrophages
from normal animals are separated from Pneumo-
cystis organisms by a semipermeable membrane,
they kill the organisms when activated by IFN-γ,
probably through release of TNF-α.157 The pro-
duction and release of TNF-α from alveolar
macrophages are increased in response to Pneumo-
cystis infection in animals as well as in monocyte
and macrophage cultures stimulated by Pneumo-
cystis organisms.158 The roles of IFN-γ and TNF-α
in macrophage function have been investigated
using IFN-γ and/or TNF-α and TNF-β receptor
knockout mice. Both TNF (TNF-α and/or TNF-β)
and IFN-γ were found to be important in the
clearance of Pneumocystis organisms.152,159,160
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Deletion of genes encoding TNF receptors, TNF-αR
and TNF-βR, or IFN-γ did not render an animal
susceptible to PcP, but deletion of TNF-αR, TNF-βR,
and IFN-γ genes facilitated development of PcP.
Although alveolar macrophages from normal
hosts bind, phagocytose and degrade Pneumocystis
organisms,134,161,162 alveolar macrophages from
Pneumocystis-infected hosts are defective in phago-
cytosis. Fleury et al163 reported that Pneumocystis
organisms were rarely seen intracellularly in alve-
olar macrophages from patients with PcP. Using
a P. murina-infected SCID mouse model, Chen 
et al164 demonstrated that phagocytosis of Pneumo-
cystis organisms was not common. Phagocytosis
of Pneumocystis organisms by macrophages is re-
duced in HIV patients with PcP, and macrophage
mannose receptor expression is decreased in these
patients.165 There was also a report that Pneumo-
cystis organisms cause alveolar macrophages to
shed mannose receptors.166 The mechanisms by
which Pneumocystis disables alveolar macrophages
are not clear. However, the transcription factor
GATA-2 is downregulated in alveolar macrophages
during P. carinii infection.167 When GATA-2 ex-
pression is knocked down in normal alveolar
macrophages, their phagocytic activity is greatly
decreased.168 These observations suggest that
GATA-2 regulates phagocytic activity of alveolar
macrophages and that Pneumocystis suppresses
GATA-2 expression in alveolar macrophages, ren-
dering them defective in phagocytosis.
The number of alveolar macrophages in pa-
tients with PcP is reduced.163,169–172 Young et al171
found that the numbers of both leukocytes and
alveolar macrophages were low in the lungs of
PcP patients. This is unusual because alveolar
macrophages are usually increased in other types
of infections in immunocompromised patients.163
Furthermore, Pneumocystis MSG is chemotactic
for monocytes;173 it should have attracted mono-
cytes from the blood to the lung and increased
alveolar macrophage number. A more quantitative
study was performed by Fleury et al.163 They de-
termined that alveolar macrophages comprised
69.5% of the total cell population in BAL fluids
from immunocompromised patients without PcP
but only 38.8% of the total cell population in BAL
fluids from patients with PcP. A similar observation
was reported by Sadaghdar et al172 that alveolar
macrophages account for 64% of total cells in
BAL fluids from AIDS patients without PcP and
only 45% in BAL fluids from AIDS patients with
PcP. The reduction in the numbers of alveolar
macrophages was found in both HIV-positive
and HIV-negative patients with PcP but was not
observed in either HIV-positive or HIV-negative
patients without PcP.
With a rat PcP model, the number of alveolar
macrophages was found to be reduced by approx-
imately 60% within 6 days after the establish-
ment of Pneumocystis infection.174 Decreasing the
organism burden by treatment with trimethoprim-
sulfamethoxazole or cessation of immunosup-
pression of rats with PcP returned the alveolar
macrophage number to normal levels,168 sug-
gesting that Pneumocystis plays a major role in the
modulation of alveolar macrophage number.
Pneumocystis organisms are known to produce
polyamines, such as spermidine, spermine, N-
acetylspermine, and N-acetylspermidine,175 and
the levels of spermine, N-acetylspermine, and N-
acetylspermidine are greatly increased in both
the alveoli and alveolar macrophages.176 When
normal alveolar macrophages are incubated with
polyamines, they undergo apoptosis. These results
indicate that Pneumocystis decreases alveolar mac-
rophage number by producing polyamines to
cause alveolar macrophage to undergo apoptosis.
It is now known that H2O2, produced when the
polyamines are metabolized, damages the mito-
chondria, leading to activation of caspase-9 and
the cascade of apoptosis. Interestingly, suppress-
ing the activity of this activated caspase-9 greatly
decreases the severity of PcP,177 suggesting that
caspase-9 can be a target for treatment of PcP.
Because alveolar macrophages are the first line 
of defense against Pneumocystis infection, it is
conceivable that Pneumocystis must overcome
this defense to survive. It appears that disabling
the phagocytic activity and decreasing the num-
ber of alveolar macrophages are the means by
which Pneumocystis ensures its survival in the host.
Therefore, preventing Pneumocystis from progress-
ing to such actions is a viable approach for treat-
ment of PcP. This possibility is being investigated.
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